Intravenous Immunoglobulin Market - By Product (IGG, IGA, IGM, IGD, IGE), Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Myasthenia Gravis, MMN, ITP), Distribution Channel (Hospital, Specialty), Global Forecast, 2023 – 2032

Intravenous Immunoglobulin Market - By Product (IGG, IGA, IGM, IGD, IGE), Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Myasthenia Gravis, MMN, ITP), Distribution Channel (Hospital, Specialty), Global Forecast, 2023 – 2032

Intravenous Immunoglobulin (IVIG) Market Size

Intravenous Immunoglobulin (IVIG) Market size is estimated to have reached USD 10.9 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 7.6% from 2023 to 2032. This growth is primarily attributed to the escalating prevalence of primary immunodeficiency disorders (PIDs) and secondary immunodeficiencies arising from various medical conditions. Global immunoglobulin industry is estimated to register over 7.4% CAGR between 2023 and 2032 driven by increasing prevalence of immunodeficiency diseases.
 

Conditions such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia necessitate regular IVIG infusions to enhance the immune system's functionality. Additionally, IVIG finds utility in the treatment of diverse autoimmune and inflammatory diseases, encompassing immune thrombocytopenic purpura (ITP), Kawasaki disease, and systemic lupus erythematosus (SLE). The rising incidence of these maladies significantly contributes to the heightened requirement for immunoglobulin treatment.
 

Furthermore, advancements in plasma collection, fractionation, and purification technologies have markedly enhanced the manufacturing and safety standards of IVIG products. These progressive developments have not only broadened the accessibility of plasma derived therapies but have also played a pivotal role in propelling market expansion. Additionally, the growing awareness surrounding immunodeficiency disorders, autoimmune diseases, and the availability of IVIG therapy has resulted in earlier diagnoses and the prompt initiation of treatments. This emerging trend notably bolsters the demand for IVIG services.
 

COVID-19 Impact

The COVID-19 pandemic has had significant ramifications on the intravenous immunoglobulin market. The outbreak of the COVID-19 epidemic generated an increased demand for essential medical supplies, among them IVIG. Notably, severely ill COVID-19 patients displayed a hyperinflammatory response, underscoring the heightened requirement for immune-modulating treatments such as IVIG. Conversely, the pandemic inflicted widespread disruptions on global supply chains, including those integral to plasma collection and IVIG production. The imposition of lockdowns, coupled with reduced donor turnout and safety apprehensions, created challenges for plasma collection facilities.
 

Furthermore, a number of clinical research endeavours and studies have been undertaken to explore the potential efficacy of IVIG in addressing specific aspects of COVID-19. These trials aimed to investigate the impact of IVIG on the immune response and cytokine storms observed in severe COVID-19 cases. Additionally, the strain placed on healthcare systems by the pandemic prompted recalibrations of healthcare priorities. In certain instances, resources were redirected towards COVID-19-related care, potentially affecting the supply and distribution of IVIG.
 

As the pandemic unfolded and healthcare systems adapted to new paradigms, the IVIG market encountered further complexities. While the immediate effects of the pandemic on the IVIG market were discernible during its initial phases, the enduring consequences of the pandemic on healthcare systems, patient behaviours, and resource allocation have precipitated shifts in market dynamics extending beyond the acute crisis.
 

Intravenous Immunoglobulin (IVIG) Market Trends

The market is undergoing transformation due to several influential trends that are shaping its trajectory of growth and advancement. Among the pivotal trends observed within this market are the increasing utilization of IVIG in the treatment of neurological disorders, the expansion of personalized medicine principles into IVIG therapy, the ascent of emerging immunomodulatory treatments, the transition from hospital-centric care to alternative healthcare settings affecting IVIG administration, and the surging demand coupled with concerns regarding supply chain stability.
 

Furthermore, the emergence of biosimilar variants of IVIG products has introduced a new dimension of competition to the market. This trend holds the potential to enhance accessibility to IVIG therapy while simultaneously impacting the dynamics of pricing. Additionally, breakthroughs in plasma collection technologies have been pivotal, aiming to enhance efficiency and yield in the extraction of high-quality plasma. These advancements are of paramount importance in ensuring a consistent supply of plasma for the production of IVIG. Collectively, these trends are poised to propel the growth of the market.
 

Intravenous Immunoglobulin (IVIG) Market Analysis

Based on product, the intravenous immunoglobulin market encompasses categories such as services, IgG, IgA, IgM, IgD, and IgE. During the year 2022, the IgG segment dominated the market, constituting the largest share. This is primarily attributed to the remarkable versatility of IgG, which encompasses a diverse array of functions within the immune system. Among its pivotal roles are pathogen neutralization, facilitation of phagocytosis, and modulation of immune responses. This adaptability renders IgG a highly appealing choice for the treatment of a wide spectrum of ailments.
 

Furthermore, the application of IgG therapy extends across a myriad of medical conditions. These encompass primary immunodeficiency disorders (PIDs), autoimmune diseases, neurological disorders, and beyond. The extensive array of indications significantly broadens the scope of patients who can derive benefits from IgG therapy.
 

Based on application, the intravenous immunoglobulin market is segmented as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, guillain-barre syndrome, and other applications. The immunodeficiency diseases held a dominant business share of around 34.7% in 2022 and is expected to grow at a significant pace during the analysis period. In PIDs, the immune system fails to produce adequate levels of antibodies needed to fight infections. IVIG therapy provides these patients with a supplemental source of functional antibodies, helping to prevent infections and maintain their health. However, growing awareness of immunodeficiency diseases and advances in diagnostic techniques have led to earlier and more accurate diagnoses. This has increased the demand for IVIG therapy as a timely and effective treatment.
 

Based on distribution channel, the intravenous immunoglobulin market is segmented as hospital pharmacy, specialty pharmacy, and other distribution channels. The hospital pharmacy segment held a dominant market share of 61.4% in 2022 and is expected to grow at a significant pace between 2023 to 2032. Hospital pharmacies are dedicated to providing patient-centric care. IVIG therapy often requires careful dosing, monitoring, and coordination. Hospital pharmacists ensure that patients receive the right dosage and appropriate treatment plans tailored to their specific conditions. Also, hospital pharmacists are highly trained professionals with expertise in medication management, drug interactions, and patient safety. IVIG therapy involves complex dosing and administration considerations, making the involvement of hospital pharmacists crucial to ensure safe and effective treatment.
 

North America intravenous immunoglobulin market accounted for the largest share of 52.3% in 2022 and is anticipated to grow at 7.7% during the forecast timeframe. North America has a relatively high prevalence of immune-mediated diseases, autoimmune disorders, and primary immunodeficiency diseases (PIDs). This high disease burden creates a substantial demand for IVIG therapy to manage these conditions.
 

Furthermore, North America leads in technological advancements, including improved IVIG administration methods, home-based infusion technologies, and monitoring tools. These advancements enhance patient convenience and adherence to therapy, leading to the regional growth.
 

Intravenous Immunoglobulin Market Share

Some of the major market players operating in the intravenous immunoglobulin are

• Takeda Pharmaceutical Company Limited
• Grifols SA
• CSL Behring
• ADMA Biologics
• Octapharma AG
• Baxter International Inc
• LFB Biotechnologies
• China Biologics Products Inc.
• Kedrion Biopharma
•  Intas Pharmaceuticals

These players focus on strategic partnerships, new product & service launch for market expansion.
 

Intravenous Immunoglobulin Industry News

• In February 2021, Pfizer Inc. announced that the US Food and Drug Administration (FDA) approved the supplementary Biologics Licence Application (sBLA) for PANZYGA, an IVIG to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological condition affecting the peripheral nerves.
   
• In January 2023, Eisai Co., Ltd., and Biogen Inc. announced that the FDA has authorised lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) for the treatment of Alzheimer's disease (AD).
   

The intravenous immunoglobulin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Product, 2018 - 2032 (USD Million)

• IgG
• IgA
• IgM
• IgD
• IgE

By Application, 2018 - 2032 (USD Million)

• Hypogammaglobulinemia
• Chronic Inflammatory demyelinating polyneuropathy (CIDP)
• Immunodeficiency diseases
• Myasthenia gravis
• Multifocal motor neuropathy
• Idiopathic thrombocytopenic purpura (ITP)
• Inflammatory myopathies
• Specific antibody deficiency
• Guillain-Barre syndrome
• Other applications

By Distribution Channel, 2018 - 2032 (USD Million)

• Hospital pharmacy
• Specialty pharmacy
• Other distribution channels

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa